<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05022329</url>
  </required_header>
  <id_info>
    <org_study_id>3750</org_study_id>
    <nct_id>NCT05022329</nct_id>
  </id_info>
  <brief_title>COVID-19 Vaccine Boosters in Patients With CKD</brief_title>
  <acronym>BOOST KIDNEY</acronym>
  <official_title>A Multi-Centre 12 Month Parallel-Group Randomized Control Trial of BNT162b2 Versus mRNA( Messenger Ribonucleic Acid) -1273 COVID-19 Vaccine Boosters in Chronic Kidney Disease and Dialysis Patients With Poor Humoral Response Following COVID-19 ( Corona Virus Disease of 2019)Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunnybrook Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scarborough General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Providence Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a 12-month, four-arm parallel-group randomized control trial of Pfizer-BioNTech&#xD;
      versus MODERNA COVID-19 (Corona Virus disease 2019)vaccine boosters in chronic kidney disease&#xD;
      and dialysis patients with poor humoral response following COVID-19 vaccination, in&#xD;
      collaboration with 5 dialysis centers in Ontario and British Columbia, Canada .&#xD;
&#xD;
      Patients will be randomized to MODERNA or Pfizer-BioNTech COVID-19 vaccine, they may have&#xD;
      received either MODERNA or Pfizer-BioNTech COVID-19 vaccine for their initial two doses of&#xD;
      vaccine, and will be stratified by their initial vaccine type (MODERNA or Pfizer-BioNTech )&#xD;
      prior to randomization, which will result in four study groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MODERNA : Nucleocapsid Modified messenger RNA BioNTech: Bio-Pharma new Technology&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Level of Anti-RBD ( Anti Receptor Binding Domain )</measure>
    <time_frame>One month</time_frame>
    <description>to evaluate the effect of third dose COVID-19 vaccine booster (BNT162b2 versus mRNA-1273) on serologic SARS-CoV-2 response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Level of SARS-CoV-2 Antibodies (Spike, RBD-Receptor Binding Domain, NP- nucleocapsid protein)</measure>
    <time_frame>12 months</time_frame>
    <description>to evaluate the effect of third dose COVID-19 vaccine booster (BNT162b2 versus mRNA-1273)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of B and T-cell lymphocyte subsets in peripheral blood mononuclear cells (PBMC) in a subset of participants</measure>
    <time_frame>1 months</time_frame>
    <description>to evaluate SARS-CoV-2 specific B and T-Cell response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>one month</time_frame>
    <description>The safety of intervention will be evaluated with adverse event questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>will be evaluated in follow up visits at 1,3,6 and 12 months after the intervention Differences between study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with COVID-19 infections</measure>
    <time_frame>12 months</time_frame>
    <description>will be evaluated in medical records, differences between study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>12 months</time_frame>
    <description>will be evaluated in medical records, differences between the study groups</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Patients who received two doses Pfizer-BioNTech vaccine, Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients who received two doses MODERNA vaccine, Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients who received two doses Pfizer-BioNTech vaccine ,Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients who received two doses MODERNA vaccine, Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pfizer-BioNTech COVID-19 Vaccine</intervention_name>
    <description>This arm receives Pfizer-BioNTech COVID-19 Vaccine</description>
    <arm_group_label>Patients who received two doses MODERNA vaccine, Arm 2</arm_group_label>
    <arm_group_label>Patients who received two doses Pfizer-BioNTech vaccine, Arm 1</arm_group_label>
    <other_name>BNT162b2 mRNA COVID-19 Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MODERNA SARS-CoV-2 Vaccine</intervention_name>
    <description>This arm receives MODERNA SARS-CoV-2 Vaccine</description>
    <arm_group_label>Patients who received two doses MODERNA vaccine, Arm 4</arm_group_label>
    <arm_group_label>Patients who received two doses Pfizer-BioNTech vaccine ,Arm 3</arm_group_label>
    <other_name>mRNA-1273 SARS-CoV-2 Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Chronic Kidney Disease (CKD)stage 3b-5 defined as an eGFR( estimated&#xD;
             glomerular filtration rate ) of less than 45ml/min/1.73m2 or less will be eligible.&#xD;
             Stage 5 CKD will include patients receiving in-center hemodialysis, home dialysis&#xD;
             (home hemodialysis or peritoneal dialysis), vaccinated with two doses of the COVID-19&#xD;
             vaccine will be eligible for a third dose to be given 2-12 months following the second&#xD;
             dose.&#xD;
&#xD;
          -  Participants with a serum Anti-RBD (Anti-Receptor Binding Domain) relative ratio on&#xD;
             their most recent measurement below the median convalescent serum relative ratio in&#xD;
             patients with prior COVID-19.&#xD;
&#xD;
          -  Age â‰¥18 at the time of study enrolment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not vaccinated against COVID-19 vaccination.&#xD;
&#xD;
          -  Patients who received heterologous first two doses of vaccine&#xD;
&#xD;
          -  Patients with a severe allergic reaction to prior COVID-19 vaccination or any of the&#xD;
             ingredients.&#xD;
&#xD;
          -  New COVID-19 infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. Michelle Hladunewich, MD, FRCPC</last_name>
    <phone>416 480 4592</phone>
    <email>Michelle.Hladunewich@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gail Klein, MSc</last_name>
    <email>COVID-CKD@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunnybrook Health Science Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Michelle Hladunewich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>CKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

